Table 1. Patient Characteristics by PRR11 Status.

	Discovery Cohort		P	Validation Cohort		P
Parameters	N	n(%)		N	n(%)
Age
≤ 55y	25	15(60.0)	0.628	23	20(87.0)	0. 893
> 55y	24	16(66.7)		35	30(85.7)
Gender
Male	35	21(60.0)	0.453	40	35(87.5)	0.670
Femal	14	10(71.4)		18	15(83.3)
Tumor size
≤ 6cm	18	9(50.0)	0.142	27	21(77.8)	0.082
> 6cm	31	22(71.0)		31	29(93.5)
T stage
T1/T2	7	2(28.6)	0.04	46	39(84.8)	0.538
T3/T4	42	29(69.0)		12	11(91.7)
N stage
No	16	7(43.8)	0.048	30	22(73.3)	0.003
Yes	33	24(72.7)		28	28(100.0)
Differentiation
High/moderate	37	24(64.9)	0.683	54	47(87.0)	0.501
Poor	12	7(58.3)		4	3(75.0)
Disease stage
I/II	3	1(33.3)	0.267	24	17(70.8)	0.004
III/IV	46	30(65.2)		34	33(97.1)
Positive margin
No	23	14(60.9)	0.744	50	43(86.0)	0.909
Yes	26	17(65.4)		8	7(87.5)
CA199
Negative	10	4(40.0)	0.087	13*	9(69.2)	0.053
Positive	39	27(69.2)		43	39(90.7)
CA199 levels
Low	22	10(45.5)	0.020	27	21(77.8)	0.101
High	27	21(77.8)		29	27(93.1)
Overall survival
≤ 1.5 years	28	22(78.6)	0.010	29†	28(96.6)	0.019
> 1.5 years	21	9(42.9)		28	21(75.0)

NOTE.*CA199 status was available for 56 cases in the validation cohorts. † One case was lost.